^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
C-CAR011
i
Other names: C-CAR011, anti-CD19-CAR vector-transduced T cells, anti-CD19 chimeric antigen receptor T cell therapy, CD19 specific CART cells , CART-19, CBM.CD19-targeted chimeric antigen receptor T cells
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
AbelZeta Pharma, Chinese PLA General Hospital
Drug class:
CD19-targeted CAR-T immunotherapy
Related drugs:
over3years
Anti-PD-1 antibodies as a salvage therapy for patients with diffuse large B cell lymphoma who progressed/relapsed after CART19/20 therapy. (PubMed, J Hematol Oncol)
After anti-PD-1 treatment, circulating T cells were activated in responders, and no significant expansion of CART19/20 cells was detected. Our data suggest that PD-1 blockade therapy can be active in patients with relapsed/refractory DLBCL after failure of CAR T cell therapy who had PD-L1 expression in tumor cells and high PD-1 level in tumor-infiltrated T cells.
Clinical • Journal • PD(L)-1 Biomarker • IO biomarker
|
CD19 (CD19 Molecule)
|
PD-L1 expression • PD-1 elevation
|
C-CAR011
4years
C-CAR011 Treatment in Subjects With ALL After HSCT (clinicaltrials.gov)
P=N/A, N=40, Active, not recruiting, Peking University People's Hospital | Not yet recruiting --> Active, not recruiting
Clinical • Enrollment closed • CAR T-Cell Therapy
|
CD19 (CD19 Molecule)
|
C-CAR011
Share via
